Electric Fields Offer New Hope in Pancreatic Cancer Fight

BAAR, Switzerland – June 30, 2026

In the relentless and often disheartening battle against pancreatic cancer, a disease notorious for its grim prognosis, a new form of therapy is delivering a tangible measure of hope. Novocure, a global oncology company, has received the CE Mark for its Optune Pax® device, clearing the way for its use in Europe to treat locally advanced pancreatic cancer. This approval isn't just another incremental step; it represents the arrival of a novel treatment modality that has demonstrated the ability to extend life and, crucially, improve the quality of that life for patients facing one of oncology's greatest challenges.

Following its approval by the U.S. Food and Drug Administration in February 2026, the European green light for Optune Pax marks a significant milestone. The device, which is used alongside standard-of-care chemotherapy, offers a new strategy for a patient population with desperately few options. The company announced it plans to launch the device in Germany in the coming weeks, beginning its expansion into the European market.

The Unmet Need in a Devastating Disease

To understand the significance of this approval, one must first grasp the formidable nature of pancreatic cancer. It is the fifth leading cause of cancer-related death in Europe, with incidence and mortality rates continuing to climb even as they decline for other cancers. The disease is often called a “silent killer” because it rarely presents symptoms in its early, more treatable stages. Consequently, approximately 80% of patients are diagnosed only after the cancer has become locally advanced or has metastasized, rendering surgical removal impossible.

For these patients with locally advanced disease, the standard treatment pathway has been a combination of chemotherapy regimens, sometimes with radiation. While these therapies can slow disease progression, their impact on overall survival has been modest, with median survival rates hovering around 12 to 14 months. The five-year relative survival rate for all stages of pancreatic cancer is a stark 13%, a figure that has seen little improvement for decades. This grim reality has fueled an urgent, global search for innovative treatments that can break through the historical therapeutic plateau.

A New Modality: Disrupting Cancer with Electric Fields

Optune Pax is not a drug. It is a portable, non-invasive medical device that leverages a technology called Tumor Treating Fields (TTFields). This therapy introduces a fundamentally different mechanism of action into the oncologist’s toolkit. Patients wear transducer arrays on their skin over the tumor region, which deliver low-intensity, alternating electric fields directly to the cancer.

These fields are specifically tuned to disrupt the division of cancer cells. As a tumor cell attempts to replicate, the electric fields interfere with the formation of the mitotic spindle—the cellular machinery essential for pulling duplicated chromosomes apart into two new daughter cells. This disruption causes the cell to either halt its division or undergo programmed cell death. A key advantage of this approach is its relative selectivity; the physical properties of healthy cells, which divide much less frequently, make them largely unaffected by the fields. This allows TTFields to be combined with systemic chemotherapies without adding to their systemic toxicity, offering a dual-pronged attack on the tumor.

Decoding the PANOVA-3 Trial: The Data Behind the Hope

The CE Mark was granted based on compelling data from the international Phase 3 PANOVA-3 clinical trial. The study evaluated the efficacy and safety of adding Optune Pax to the standard chemotherapy combination of gemcitabine and nab-paclitaxel (gem/nab-pac) for patients with locally advanced pancreatic cancer.

The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in median overall survival. In the intent-to-treat population of 571 patients, those who received Optune Pax plus chemotherapy lived for a median of 16.2 months, compared to 14.2 months for those who received chemotherapy alone. While a two-month extension may seem modest on paper, in the context of this aggressive disease, it is a clinically meaningful advancement.

Perhaps more impactful for patients’ day-to-day lives was the device's effect on pain, a debilitating and common symptom of advancing pancreatic cancer. The PANOVA-3 trial showed that patients treated with the Optune Pax combination had a median time to pain progression of 15.2 months, a remarkable 6.1-month extension compared to the 9.1 months seen in the chemotherapy-only group. This significant delay in the onset of severe pain directly translates to a longer period of better quality of life.

“Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival rates have remained low for decades,” said Teresa Macarulla, MD, PhD, Head of the Department of Medical Oncology at Hospital Clínic Barcelona. “In addition, Optune Pax was also shown to delay pain progression, a debilitating symptom of pancreatic cancer. This is a promising treatment for patients who have an urgent need for new options.”

The device was well-tolerated. As expected with a wearable therapy, the most common side effects were mild-to-moderate skin irritation under the arrays. Crucially, the addition of Optune Pax did not increase the systemic toxicities associated with chemotherapy, confirming its favorable safety profile when used as a concomitant treatment.

From Lab to Patient: The Path to European Access

Receiving the CE Mark is a critical regulatory victory, but it is the first step in a complex journey to ensure broad patient access across Europe. Unlike a centralized drug approval, medical device reimbursement is handled on a country-by-country basis, requiring negotiations with national health technology assessment (HTA) bodies.

Novocure's planned launch in Germany signals the company’s strategy to begin with markets that have more established pathways for innovative technology adoption. “The CE Mark designation is a critical milestone in our efforts to bring Optune Pax to people living with locally advanced pancreatic cancer, a disease in need of new treatment options,” said Anne Calixte de Lembeye, Senior Vice President, EMEA and Canada at Novocure. “We are proud of this achievement and are committed to working with national agencies to secure access to Optune Pax for patients with pancreatic cancer who may benefit from treatment.”

For thousands of patients and their families across Europe, this new approval represents more than just a scientific achievement; it offers a new front in a difficult war, providing a validated tool that can extend survival and preserve quality of life when it matters most.